
Joerg Beyer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8021766/publications.pdf Version: 2024-02-01



LOEDC REVED

#	Article	IF	CITATIONS
1	Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. British Journal of Cancer, 2022, 126, 1140-1144.	2.9	23
2	Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses. European Urology Open Science, 2022, 40, 16-18.	0.2	6
3	The Role of Frozen Section Examination During Inguinal Exploration in Men with Inconclusive Testicular Tumors: A Systematic Review and Meta-analysis. European Urology Focus, 2021, 7, 1400-1402.	1.6	16
4	Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2671-2679.	1.2	7
5	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. Journal of Clinical Oncology, 2021, 39, 1553-1562.	0.8	83
6	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. Journal of Clinical Oncology, 2021, 39, 1563-1574.	0.8	108
7	Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma. Journal of Clinical Oncology, 2020, 38, 1322-1331.	0.8	23
8	Clinicopathological characteristics, risk factors and outcomes of patients with para- /testicular sarcoma: A systematic review. European Urology Open Science, 2020, 19, e404.	0.2	1
9	Risk factors and treatment outcomes of 239 patients with testicular granulosa cell tumors: a systematic review of published case series data. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2829-2841.	1.2	23
10	Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: Analysis of published case series data. European Urology Open Science, 2020, 21, S243.	0.2	1
11	HNF1β is a sensitive and specific novel marker for yolk sac tumor: a tissue microarray analysis of 601 testicular germ cell tumors. Modern Pathology, 2020, 33, 2354-2360.	2.9	13
12	Sertoli Cell Tumors of the Testes: Systematic Literature Review and Meta-Analysis of Outcomes in 435 Patients. Oncologist, 2020, 25, 585-590.	1.9	22
13	Risk Factors and Treatment Outcomes of 1,375 Patients with Testicular Leydig Cell Tumors: Analysis of Published Case Series Data. Journal of Urology, 2020, 203, 949-956.	0.2	30
14	Prognostic factors in advanced seminoma: An analysis from the IGCCCG Update Consortium Journal of Clinical Oncology, 2020, 38, 386-386.	0.8	14
15	Reply by Authors. Journal of Urology, 2020, 203, 956-956.	0.2	0
16	CXCL12 expression is an adverse predictor for disease recurrence in patients with metastatic non-seminomatous testicular germ cell tumors. BMC Cancer, 2019, 19, 802.	1.1	4
17	A systematic review of treatment outcomes in localised and metastatic spermatocytic tumors of the testis. Journal of Cancer Research and Clinical Oncology, 2019, 145, 3037-3045.	1.2	16
18	Redefining the IGCCCG classification in advanced non-seminoma. Annals of Oncology, 2019, 30, v357-v358.	0.6	12

#	Article	IF	CITATIONS
19	Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment. Journal of Cancer Research and Clinical Oncology, 2019, 145, 781-785.	1.2	14
20	Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma. Neoplasia, 2019, 21, 247-256.	2.3	55
21	Reply to V. Murthy et al. Journal of Clinical Oncology, 2019, 37, 938-939.	0.8	0
22	Prognostic factors in metastatic germ ell cancer. Andrology, 2019, 7, 475-478.	1.9	4
23	Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma Journal of Clinical Oncology, 2019, 37, 510-510.	0.8	1
24	RefraktÃ r e Hodentumore und Rezidive: Therapie. Springer Reference Medizin, 2019, , 1-8.	0.0	0
25	Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland. Clinical Genitourinary Cancer, 2018, 16, e711-e718.	0.9	1
26	Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy. British Journal of Cancer, 2018, 118, 825-830.	2.9	58
27	Improved survival in metastatic germ-cell cancer. Annals of Oncology, 2018, 29, 347-351.	0.6	14
28	Response to first-line treatment and histology are associated with achieving complete remission after the first salvage high-dose chemotherapy in relapsing germ cell tumor patients. Bone Marrow Transplantation, 2018, 53, 820-825.	1.3	3
29	High β-1,4-Galactosyltransferase-I expression in peripheral T-lymphocytes is associated with a low risk of relapse in germ-cell cancer patients receiving high-dose chemotherapy with autologous stem cell reinfusion. Oncolmmunology, 2018, 7, e1423169.	2.1	10
30	Developing an Integrative Treatment Program for Cancer-Related Fatigue Using Stakeholder Engagement – A Qualitative Study. Integrative Cancer Therapies, 2018, 17, 762-773.	0.8	8
31	Re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262–70 European Urology, 2018, 73, e94-e95.	0.9	1
32	Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry. Journal of Clinical Oncology, 2018, 36, 3381-3387.	0.8	49
33	Data of efficacy and toxicity for Radium-223 in patients with metastatic castration- resistant prostate cancer in real-life setting: A single-center experience. European Urology Supplements, 2018, 17, e2851.	0.1	0
34	The role of frozen section examination (FSE) during inguinal exploration in 1052 patients with inconclusive testicular lesions. European Urology Supplements, 2018, 17, e3005.	0.1	0
35	Palliative treatment of germ cell cancer. Cancer Treatment Reviews, 2018, 71, 102-107.	3.4	19
36	MP37-16 RISK FACTORS FOR MALIGNANCY IN PATIENTS WITH LEYDIG CELL TUMORS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 1'375 PATIENTS. Journal of Urology, 2018, 199, .	0.2	0

ą	#	Article	IF	CITATIONS
;	37	ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, 1658-1686.	0.6	228
:	38	Hodentumor: Medikamentöse Therapie bei refraktÃ ¤ en Tumoren und Rezidiven. Springer Reference Medizin, 2018, , 1-8.	0.0	0
;	39	How we treat germ cell cancers. Cancer, 2017, 123, 2190-2192.	2.0	4
4	40	MP80-08 DIAGNOSTIC VALUE OF FROZEN SECTION EXAMINATION (FSE) DURING INGUINAL EXPLORATION IN PATIENTS WITH INCONCLUSIVE TESTICULAR LESIONS. Journal of Urology, 2017, 197, .	0.2	0
4	41	MP80-17 CXCL12 IS A PREDICTOR FOR DISEASE RECURRENCE INÂPATIENTS WITH METASTATIC NON-SEMINOMA. Journal of Urology, 2017, 197, .	0.2	0
4	42	High-dose chemotherapy as salvage treatment in germ-cell cancer: when, in whom and how. World Journal of Urology, 2017, 35, 1177-1184.	1.2	6
4	43	Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer. European Urology Focus, 2017, 3, 280-286.	1.6	2
4	44	Risk stratification for venous thromboembolism in patients with testicular germ cell tumors. PLoS ONE, 2017, 12, e0176283.	1.1	39
٩	45	Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma. Journal of Clinical Oncology, 2017, 35, 194-200.	0.8	41
4	46	FDG PET scan (PET) positive residual lesions after chemotherapy (chemo) for metastatic seminoma: Results of an International Global Germ Cell Cancer Group (G3) registry Journal of Clinical Oncology, 2017, 35, 4521-4521.	0.8	11
4	47	MP81-03 SYSTEMIC INFLAMMATORY RESPONSE MARKERS IN PATIENTS WITH METASTATIC GERM CELL TUMORS UNDERGOING CHEMOTHERAPY MIGHT BE OF PROGNOSTIC VALUE. Journal of Urology, 2016, 195, .	0.2	0
4	48	Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options—An Analysis From the Global Germ Cell Cancer Group. Journal of Clinical Oncology, 2016, 34, 345-351.	0.8	69
4	49	L1-CAM is commonly expressed in testicular germ cell tumours. Journal of Clinical Pathology, 2016, 69, 460-462.	1.0	3
ł	50	Hodentumor: Medikamentöse Therapie bei refraktäen Tumoren und Rezidiven. , 2016, , 1777-1782.		0
;	51	2601 Outcome of relapses after adjuvant carboplatin in clinical stage I seminoma. European Journal of Cancer, 2015, 51, S511-S512.	1.3	1
ł	52	Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. Annals of Oncology, 2015, 26, 833-838.	0.6	57
	53	First salvage treatment of germ cell tumor patients with bone metastases: retrospective analysis of a large international database. Journal of Cancer Research and Clinical Oncology, 2015, 141, 923-931.	1.2	7
;	54	Frequent PD-L1 expression in testicular germ cell tumors. British Journal of Cancer, 2015, 113, 411-413.	2.9	126

#	Article	IF	CITATIONS
55	Emerging Therapeutic Targets for Male Germ Cell Tumors. Current Oncology Reports, 2015, 17, 54.	1.8	9
56	Editorial Comment from Dr Beyer to Identification of a subgroup with worse prognosis among patients with poorâ€risk testicular germ cell tumor. International Journal of Urology, 2015, 22, 929-930.	0.5	0
57	Early Gains Versus Late Pains: Management Options in Stage I Testicular Cancer. Journal of Clinical Oncology, 2015, 33, 2318-2318.	0.8	6
58	Frequent expression of PD-L1 in testicular germ cell tumors Journal of Clinical Oncology, 2015, 33, 379-379.	0.8	1
59	First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). Journal of Cancer Research and Clinical Oncology, 2014, 140, 1211-20.	1.2	11
60	Miracles don't happen any more. Annals of Oncology, 2014, 25, 1679-1680.	0.6	1
61	A single arm, open-label multicenter phase II trial of everolimus in patients with relapsed/refractory germ cell cancer (RADIT) Journal of Clinical Oncology, 2014, 32, e15535-e15535.	0.8	1
62	Maligne Hodentumoren. , 2014, , 677-782.		1
63	Hodentumor: Medikamentöse Therapie bei refraktäen Tumoren und Rezidiven. , 2014, , 1-8.		0
64	Prognostic impact of LDH levels in patients with relapsed/refractory seminoma. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1311-1316.	1.2	12
65	Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2013, 24, vi125-vi132.	0.6	236
66	Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors. Annals of Oncology, 2013, 24, 322-328.	0.6	26
67	The Role of Residual Tumor Resection in the Management of Nonseminomatous Germ Cell Cancer of Testicular Origin. Thoracic and Cardiovascular Surgeon, 2012, 60, 405-412.	0.4	24
68	Sequential Versus Single High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: Long-Term Results of a Prospective Randomized Trial. Journal of Clinical Oncology, 2012, 30, 800-805.	0.8	94
69	Spannungsfaktoren für die Bemessung punktgestützter Verglasungen. Stahlbau, 2012, 81, 719-727.	0.2	5
70	Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse. Experimental Hematology and Oncology, 2012, 1, 6.	2.0	2
71	Salvage Therapy: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. Urology, 2011, 78, S469-S474.	0.5	0
72	ls High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial. Journal of Cancer, 2011, 2, 374-377.	1.2	55

#	Article	IF	CITATIONS
73	Interdisciplinary Evidence-Based Recommendations for the Follow-Up of Early Stage Seminomatous Testicular Germ Cell Cancer Patients. Strahlentherapie Und Onkologie, 2011, 187, 158-166.	1.0	22
74	Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database. Journal of Clinical Oncology, 2011, 29, 2178-2184.	0.8	226
75	Superior survival after sequential high-dose chemotherapy (HDCT) as compared to single HDCT in patients with relapsed or refractory germ cell tumors (GCT): Six-year long-term follow-up of a prospective, randomized phase II trial Journal of Clinical Oncology, 2011, 29, 4507-4507.	0.8	1
76	High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors. Annals of Oncology, 2010, 21, 820-825.	0.6	68
77	Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy. Journal of Clinical Oncology, 2010, 28, 4906-4911.	0.8	267
78	Patterns of Relapse after Chemotherapy in Patients with High-Risk Non-Seminomatous Germ Cell Tumor. Oncology, 2010, 78, 47-53.	0.9	10
79	High Dose Chemotherapy as Salvage Treatment for Unresectable Late Relapse Germ Cell Tumors. Journal of Urology, 2010, 184, 168-173.	0.2	33
80	Highâ€dose chemotherapy in nonseminomatous germ cell cancer. BJU International, 2009, 104, 1398-1403.	1.3	6
81	Ensemble Learning for Multi-source Information Fusion. Lecture Notes in Computer Science, 2009, , 748-756.	1.0	2
82	Maligne Hodentumoren. , 2009, , 637-738.		0
83	High-dose chemotherapy (HDCT) as second salvage treatment in patients with multiple relapsed or refractory germ cell tumors. Journal of Clinical Oncology, 2009, 27, 5082-5082.	0.8	1
84	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. European Urology, 2008, 53, 478-496.	0.9	488
85	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. European Urology, 2008, 53, 497-513.	0.9	243
86	Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: Evaluation of a prognostic score for survival after high-dose chemotherapy. European Journal of Cancer, 2008, 44, 237-243.	1.3	18
87	Analysis of paclitaxel-based high-dose chemotherapy (Tax HD-VIP) in 18 patients (pts) with relapsed germ-cell tumors (GCT). Journal of Clinical Oncology, 2008, 26, 16055-16055.	0.8	0
88	Single Versus Sequential High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: A Prospective Randomized Multicenter Trial of the German Testicular Cancer Study Group. Journal of Clinical Oncology, 2007, 25, 2778-2784.	0.8	117
89	Phase I/II Study of Sequential Dose-Intensified Ifosfamide, Cisplatin, and Etoposide Plus Paclitaxel As Induction Chemotherapy for Poor Prognosis Germ Cell Tumors by the German Testicular Cancer Study Group. Journal of Clinical Oncology, 2007, 25, 5742-5747.	0.8	42

#	Article	IF	CITATIONS
91	Germ-cell tumors. New England Journal of Medicine, 2007, 357, 1772-3; author reply 1773-4.	13.9	Ο
92	Activity of thalidomide in patients with platinum-refractory germ-cell tumours. European Journal of Cancer, 2006, 42, 1775-1779.	1.3	42
93	Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). Annals of Oncology, 2006, 17, 276-280.	0.6	78
94	Single versus sequential high-dose chemotherapy (HDCT) in patients with relapsed or refractory germ-cell tumors (GCT). Journal of Clinical Oncology, 2006, 24, 4511-4511.	0.8	4
95	Evaluation of prognosis in relapsed germ cell tumors: Identification of patients who profit from high dose chemotherapy (HDCT). Journal of Clinical Oncology, 2006, 24, 4585-4585.	0.8	1
96	Conditioning with 8 Gy Total Body Irradiation and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: Projected 4-Year Update Blood, 2006, 108, 3016-3016.	0.6	0
97	Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Blood, 2005, 106, 3314-3321.	0.6	67
98	Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. British Journal of Haematology, 2005, 129, 631-643.	1.2	109
99	Repeat Retroperitoneal Lymphadenectomy in Advanced Testicular Cancer. European Urology, 2005, 47, 64-71.	0.9	67
100	High-resolution ultrasonography in gastrointestinal graft-versus-host disease. Annals of Hematology, 2005, 84, 33-39.	0.8	27
101	European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Annals of Oncology, 2004, 15, 1377-1399.	0.6	441
102	Residual Tumor Resection After High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Cancer. Journal of Clinical Oncology, 2004, 22, 3713-3719.	0.8	93
103	Combination Chemotherapy With Gemcitabine Plus Oxaliplatin in Patients With Intensively Pretreated or Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group. Journal of Clinical Oncology, 2004, 22, 108-114.	0.8	146
104	The role of high-dose chemotherapy in relapsed germ cell tumors. World Journal of Urology, 2004, 22, 25-32.	1.2	5
105	Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin?s disease. Annals of Hematology, 2004, 83, 237-241.	0.8	30
106	Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biology of Blood and Marrow Transplantation, 2004, 10, 698-708.	2.0	103
107	Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Annals of Hematology, 2003, 82, 336-342.	0.8	97
108	Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies. Annals of Hematology, 2003, 82, S175-S185.	0.8	77

#	Article	IF	CITATIONS
109	Salvage-Therapie von Patienten mit Hodentumoren und Rezidiv oder inkomplettem Ansprechen auf Prim�rbehandlung. Onkologe, 2003, 9, 997-1003.	0.7	0
110	Kooperation statt Korruption. Onkologe, 2003, 9, 1355-1361.	0.7	1
111	Current aspects of high-dose chemotherapy in germ-cell tumors. Critical Reviews in Oncology/Hematology, 2003, 47, 237-248.	2.0	5
112	Extragonadal germ cell tumors: relation to testicular neoplasia and management options. Apmis, 2003, 111, 49-63.	0.9	49
113	Bacterial contamination of ex vivo processed PBPC products under clean room conditions. Transfusion, 2003, 43, 1587-1595.	0.8	21
114	Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplantation, 2003, 31, 1089-1095.	1.3	135
115	Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell support. European Journal of Cancer, 2003, 39, 775-782.	1.3	6
116	Evidence of a Graft-Versus-Leukemia Effect in Chronic Lymphocytic Leukemia After Reduced-Intensity Conditioning and Allogeneic Stem-Cell Transplantation: The Cooperative German Transplant Study Group. Journal of Clinical Oncology, 2003, 21, 2747-2753.	0.8	238
117	Long-Term Results of First-Line Sequential High-Dose Etoposide, Ifosfamide, and Cisplatin Chemotherapy Plus Autologous Stem Cell Support for Patients With Advanced Metastatic Germ Cell Cancer: An Extended Phase I/II Study of the German Testicular Cancer Study Group. Journal of Clinical Oncology. 2003. 21. 4083-4091.	0.8	154
118	Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. Annals of Oncology, 2003, 14, 1525-1529.	0.6	49
119	Ethics in Oncology. Stormy Weather Ahead, but also the Promise of a Better World?. Oncology Research and Treatment, 2003, 26, 522-523.	0.8	1
120	First-Line and Salvage High-Dose Chemotherapy in Patients with Germ-Cell Tumors. , 2003, , 253-262.		0
121	Extragonadal Germ Cell Tumors of the Mediastinum and Retroperitoneum: Results From an International Analysis. Journal of Clinical Oncology, 2002, 20, 1864-1873.	0.8	423
122	Toxicity of High-Dose Carboplatin: Ultrafiltered and Not Total Plasma Pharmacokinetics Is of Clinical Relevance. Journal of Clinical Pharmacology, 2002, 42, 762-773.	1.0	14
123	Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Annals of Oncology, 2002, 13, 1017-1028.	0.6	119
124	Activity of Oxaliplatin in Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group. Journal of Clinical Oncology, 2002, 20, 2031-2037.	0.8	99
125	High-dose versus conventional-dose chemotherapy asfirst-salvage treatment in patients with non-seminomatousgerm-cell tumors: a matched-pair analysis. Annals of Oncology, 2002, 13, 599-605.	0.6	114
126	Influence of amifostine on reconstitution of lymphocyte subpopulations after conventional- and high-dose chemotherapy in patients with germ cell tumor. Annals of Hematology, 2002, 81, 717-722.	0.8	3

#	Article	IF	CITATIONS
127	High-dose chemotherapy as salvage treatment for seminoma. Bone Marrow Transplantation, 2002, 30, 157-160.	1.3	15
128	Chemotherapy in patients with metastatic or relapsed germ-cell tumours. Cancer Treatment Reviews, 2001, 27, 283-288.	3.4	6
129	Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor. Annals of Oncology, 2001, 12, 1151-1155.	0.6	35
130	Salvage Treatment With Paclitaxel, Ifosfamide, and Cisplatin Plus High-Dose Carboplatin, Etoposide, and Thiotepa Followed by Autologous Stem-Cell Rescue in Patients With Relapsed or Refractory Germ Cell Cancer. Journal of Clinical Oncology, 2001, 19, 81-88.	0.8	134
131	Second-Line Chemotherapy in Patients With Relapsed Extragonadal Nonseminomatous Germ Cell Tumors: Results of an International Multicenter Analysis. Journal of Clinical Oncology, 2001, 19, 1641-1648.	0.8	100
132	Salvage chemotherapy in relapsed germ cell tumors. World Journal of Urology, 2001, 19, 90-93.	1.2	14
133	PBPC mobilization with paclitaxel, ifosfamide, and G-CSF with or without amifostine: results of a prospective randomized trial. Transfusion, 2001, 41, 196-200.	0.8	3
134	Extragonadal seminoma. Cancer, 2001, 91, 1394-1401.	2.0	126
135	Reversed portal vein pulsatility on Doppler ultrasound secondary to an iatrogenic mediastinal haematoma. British Journal of Radiology, 2001, 74, 962-964.	1.0	3
136	Incidence of Metachronous Testicular Cancer in Patients With Extragonadal Germ Cell Tumors. Journal of the National Cancer Institute, 2001, 93, 1733-1738.	3.0	121
137	Skin involvement as the first manifestation of systemic aspergillosis in patients after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2001, 27, 753-755.	1.3	20
138	Extragonadal seminoma. , 2001, 91, 1394.		3
139	Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome. Cancer, 2001, 91, 1394-401.	2.0	25
140	First-line high-dose chemotherapy ± radiation therapy in patients with metastatic germ-cell cancer and brain metastases. Annals of Oncology, 2000, 11, 553-560.	0.6	61
141	Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer. Anti-Cancer Drugs, 2000, 11, 535-539.	0.7	21
142	The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors. Cancer, 2000, 88, 2629-2635.	2.0	40
143	Diagnosis of toxoplasmosis in bone marrow transplant recipients: comparison of PCR-based results and immunohistochemistry. Bone Marrow Transplantation, 2000, 25, 1257-1262.	1.3	49
144	Successful autologous bone marrow rescue in patients who failed peripheral blood stem cell mobilization. Annals of Hematology, 2000, 79, 681-686.	0.8	15

#	Article	IF	CITATIONS
145	Hematologic Disorders Associated With Primary Mediastinal Nonseminomatous Germ Cell Tumors. Journal of the National Cancer Institute, 2000, 92, 54-61.	3.0	176
146	The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors. , 2000, 88, 2629.		1
147	Detection of germ-cell tumor cells in peripheral blood progenitor cell harvests: impact on clinical outcome. Clinical Cancer Research, 2000, 6, 4641-6.	3.2	7
148	Gemcitabine in Patients With Relapsed or Cisplatin-Refractory Testicular Cancer. Journal of Clinical Oncology, 1999, 17, 512-512.	0.8	137
149	High-dose salvage chemotherapy. Germ-cell tumor treatment results in Germany. , 1999, 83, 839-840.		9
150	Treatment of patients with cisplatin-refractory testicular germ-cell cancer. , 1999, 83, 848-851.		30
151	First-Line High-Dose Chemotherapy Compared With Standard-Dose PEB/VIP Chemotherapy in Patients With Advanced Germ Cell Tumors: A Multivariate and Matched-Pair Analysis. Journal of Clinical Oncology, 1999, 17, 3450-3456.	0.8	161
152	Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood, 1999, 93, 3654-61.	0.6	126
153	Analysis of CD34â€Expressing Cells in Clinical Practice. Vox Sanguinis, 1998, 74, 469-475.	0.7	3
154	Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation. Bone Marrow Transplantation, 1998, 22, 579-583.	1.3	20
155	Detection of tumor cells in peripheral blood samples from patients with germ cell tumors using immunocytochemical and reverse transcriptase-polymerase chain reaction techniques. Bone Marrow Transplantation, 1998, 22, 771-775.	1.3	15
156	Prognosefaktoren bei meta-stasierten seminomatösen und nichtseminomatösen Hodentumoren. Onkologe, 1998, 4, 518-523.	0.7	2
157	Salvagetherapie rezidivierter und refraktÃ r er Hodentumoren. Onkologe, 1998, 4, 541-546.	0.7	6
158	High-dose chemotherapy with autologous stem cell support in poor-risk germ cell tumors. Annals of Hematology, 1998, 76, 183-188.	0.8	12
159	Recent strategies for the use of paclitaxel in the treatment of urological malignancies. World Journal of Urology, 1998, 16, 155-162.	1.2	16
160	High-dose chemotherapy in germ cell tumours: a large single centre experience. European Journal of Cancer, 1998, 34, 1883-1888.	1.3	53
161	Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors Journal of Clinical Oncology, 1998, 16, 3386-3391.	0.8	190
162	First-Line High-Dose Chemotherapy for 'Poor Risk' Metastatic Non-Seminomatous Testicular Germ Cell Tumors. Oncology Research and Treatment, 1998, 21, 23-25.	0.8	5

#	Article	IF	CITATIONS
163	Prognostic factors in metastatic germ cell tumors. Seminars in Oncology, 1998, 25, 174-85.	0.8	26
164	Germ cell tumors: dose-intensive therapy. Seminars in Oncology, 1998, 25, 215-23.	0.8	8
165	Considerable plasma levels of a cytotoxic etoposide metabolite in patients undergoing high-dose chemotherapy. European Journal of Cancer, 1997, 33, 978-979.	1.3	14
166	Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome. Bone Marrow Transplantation, 1997, 20, 813-819.	1.3	48
167	Herpes simplex infection of the jejunum occurring in the early post-transplantation period. Bone Marrow Transplantation, 1997, 20, 989-991.	1.3	14
168	Long term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Cancer, 1997, 79, 161-168.	2.0	57
169	Current Approaches in the Prevention of Invasive Aspergillosis. Hamatologie Und Bluttransfusion, 1997, , 485-488.	0.0	0
170	Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Cancer, 1997, 79, 161-8.	2.0	9
171	Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer Journal of Clinical Oncology, 1996, 14, 1114-1121.	0.8	84
172	Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Annals of Oncology, 1996, 7, 31-34.	0.6	134
173	High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables Journal of Clinical Oncology, 1996, 14, 2638-2645.	0.8	308
174	The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors. World Journal of Urology, 1996, 14, 354-9.	1.2	16
175	Autografting with blood progenitor cells: predictive value of preapheresis blood cell counts on progenitor cell harvest and correlation of the reinfused cell dose with hematopoietic reconstitution. Annals of Hematology, 1995, 71, 227-234.	0.8	8
176	WÄ ¤ neübertragung in Rieselbettreaktoren. Chemie-Ingenieur-Technik, 1995, 67, 1110-1111.	0.4	0
177	Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Annals of Hematology, 1995, 71, 287-291.	0.8	72
178	Autografting with blood progenitor cells: predictive value of preapheresis blood cell counts on progenitor cell harvest and correlation of the reinfused cell dose with hematopoietic reconstitution. Annals of Hematology, 1995, 71, 227-234.	0.8	50
179	Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison Journal of Clinical Oncology, 1995, 13, 1328-1335.	0.8	266
180	Risk of Secondary Leukemia Following High Cumulative Doses of Etoposide During Chemotherapy for Testicular Cancer. Journal of the National Cancer Institute, 1995, 87, 58-59.	3.0	45

#	Article	IF	CITATIONS
181	High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group Journal of Clinical Oncology, 1994, 12, 1223-1231.	0.8	218
182	Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients. Antimicrobial Agents and Chemotherapy, 1994, 38, 911-917.	1.4	67
183	CD 34 Immunotyping of blasts in myelodysplasia. Annals of Hematology, 1994, 68, 77-80.	0.8	15
184	Use of amphotericin B aerosols for the prevention of pulmonary aspergillosis. Infection, 1994, 22, 143-148.	2.3	51
185	Treatment intensification in disseminated germ-cell tumors. World Journal of Urology, 1994, 12, 207-13.	1.2	8
186	Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Journal of Cancer Research and Clinical Oncology, 1994, 120, 754-757.	1.2	34
187	Microbiologic Contamination of Peripheral Blood Stem Cell Autografts. Vox Sanguinis, 1994, 67, 32-35.	0.7	50
188	P163 clinical pharmacokinetics of high-dose carboplatin with special emphasis on protein binding. European Journal of Pharmaceutical Sciences, 1994, 2, 159.	1.9	0
189	P162 clinical pharmacokinetics of etoposide during high-dose treatment in relation to toxicity. European Journal of Pharmaceutical Sciences, 1994, 2, 159.	1.9	0
190	Tumor-associated antigens in effusions of malignant and benign origin. The Clinical Investigator, 1993, 71, 437-44.	0.6	17
191	Automated Processing of Human Bone Marrow Grafts for Transplantation. Vox Sanguinis, 1993, 65, 293-299.	0.7	16
192	Comparison of 5 vs 10 μg/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancer. Annals of Hematology, 1993, 67, 75-79.	0.8	11
193	Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy, 1993, 37, 1367-1369.	1.4	65
194	Graft-versus-host disease or graft-versus-host-like syndrome. Blood, 1992, 80, 2948-50.	0.6	1